类风湿性关节炎患者中普立米德的临床与生化评估。

A clinical and biochemical assessment of prinomide in patients with rheumatoid arthritis.

作者信息

Bird H A, Hill J, Dixon J S, Bojar R, Traficante A, Catalano M A, Adair S F, Liauw L, Sussman H, Rotman H

机构信息

Clinical Pharmacology Unit, Royal Bath Hospital, North Yorkshire, England.

出版信息

J Rheumatol. 1989 Apr;16(4):448-54.

PMID:2664168

Abstract

Prinomide (CGS-10787B), a potential disease modifying drug, was evaluated clinically and biochemically in 15 patients with active rheumatoid arthritis. The single group study design included monthly assessments of 7 clinical measures and 22 laboratory measures. Twelve patients completed 24 weeks' therapy with prinomide 1.2 g/day. All clinical variables showed improvement which consistently reached statistical significance for articular index from Week 8 (p less than 0.01), for summated change score from Week 12 (p less than 0.01) and for pain score from Week 16 (p less than 0.05). Sustained significant improvement in laboratory variables was seen by Week 2 for erythrocyte sedimentation rate and platelet count (both p less than 0.05), and by Week 4 for plasma viscosity (p less than 0.01), IgG, IgA, IgM (all p less than 0.05).

摘要

咪诺米特（CGS - 10787B）是一种可能具有改善病情作用的药物，对15例活动性类风湿关节炎患者进行了临床和生化评估。单组研究设计包括每月对7项临床指标和22项实验室指标进行评估。12例患者完成了为期24周、每日服用1.2克咪诺米特的治疗。所有临床变量均有改善，关节指数从第8周起持续达到统计学显著性（p小于0.01），累计变化评分从第12周起（p小于0.01），疼痛评分从第16周起（p小于0.05）。实验室变量方面，红细胞沉降率和血小板计数在第2周时出现持续显著改善（均p小于0.05），血浆粘度在第4周时出现显著改善（p小于0.01），IgG、IgA、IgM在第4周时均出现显著改善（均p小于0.05）。